Quickening Oncology Clinical Improvement in Asia.


96 views
Uploaded on:
Category: Music / Dance
Description
Quickening Oncology Clinical Development in Asia. Pharma Trials Asia 2010, ... 5 Asian markets (Taiwan, Thailand, Singapore, Malaysia, Philippines) ...
Transcripts
Slide 1

Quickening Oncology Clinical Development in Asia Pharma Trials Asia 2010, Singapore eighteenth March Dr. Ross Horsburgh, VP Asia/Pacific, Kendle International

Slide 2

What\'s happened so far Prehistory Asia Different Asia Big Asia Global Pre 1990 Ad-hoc Investigator-premium trials Early 90\'s Asia particular illnesses or inquiries Late 90\'s Large scale trials Rescue concentrates NOW Inclusion in worldwide advancement

Slide 3

Oncology as of now a key range for Asia

Slide 4

IRESSA still an extraordinary contextual analysis for Asia ISEL trial: - 5 Asian markets (Taiwan, Thailand, Singapore, Malaysia, Philippines) - 342 Asian patients of aggregate 1692 comprehensively Overall no distinction in survival Iressa versus fake treatment However pre-arranged sub-bunch examination of Asian patient accomplice demonstrated noteworthy advantage

Slide 5

Oncology DD in Asia was measurements driven

Slide 6

Oncology now full range in Asia

Slide 7

The inquiries have developed Prehistory Asia Different Asia Big Asia Global Should we? Do what? How to Build? How to advance? 7

Slide 8

Asia\'s vital contrasts Large populace Lower costs (espec. Strategies) Fast execution Focus on science & instruction Lack of legacy frameworks/attitude Rapid development High rate of progress (locales/staff/CRO\'s/newco\'s/controls)

Slide 9

Ensure you think "key open doors" not "operational issues" No novel operational difficulties Asia wont take after EU/USA  " on the off chance that it would appear that they did is it the best approach ?" Winners will best endeavor the distinctions Asia\'s most prominent commitment will be advancement -process -science/items

Slide 10

(1) Drive Efficiencies Large populace Lower costs (espec. Methodology) Fast execution Focus on science & instruction Lack of legacy frameworks/attitude Rapid development High rate of progress (destinations/work force/CRO\'s/newco\'s/directions) 10

Slide 11

(2) Leverage the science & advancement Large populace Lower costs (espec. Methodology) Fast execution Focus on science & instruction Lack of legacy frameworks/outlook Rapid development High rate of progress (destinations/faculty/CRO\'s/newco\'s/directions) 11

Slide 12

(3) Maximize Market Access returns Large populace Lower costs (espec. Methods) Fast execution Focus on science & training Lack of legacy frameworks/mentality Rapid development High rate of progress (locales/work force/CRO\'s/newco\'s/directions) 12

Slide 13

Where are the best communities for oncology? KOREA "R" and also "D" CHINA Toughest, yet greatest business sector access upside TAIWAN - long family in Oncology INDIA Great measurements Great advancement PHILIPPINES - steady entertainer SINGAPORE - quick to begin, unsurprising administrative, Ph1 & Translational

Slide 14

What is the part of outsourcing? Strategic Local CRO Do it yourself CRO do it all Global CRO Strategic 14

Slide 15

Summary Asia is as of now a key district for Oncology DD Asia is distinctive - Think vital +ve not operational –ve Open personality on what/how/how much/where to outsource and augment the CRO\'s additional quality

Recommended
View more...